Biomarker profiling of plasma from acute coronary syndrome patients. Application of ProteinChip Array analysis

International Angiology

Volumn 23, Issue 3, 2004, Pages 246-254

  Florian Kujawski, M ^a,b   Hussain, W ^a   Chyna, B ^a   Kahn, S ^a   Hoppensteadt, D ^a   Leya, F ^a   Fareed, J ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Biological markers; Coronary disease; Molecular profiling

Indexed keywords

ALBUMIN; AUTACOID; BIOLOGICAL MARKER; PROTEINASE;

ANION EXCHANGE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE PREDISPOSITION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN MICROARRAY; PROTEOMICS; RISK ASSESSMENT; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ACUTE DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY DISEASE; HUMANS; HYDROXYLATION; MASS SPECTROMETRY; MOLECULAR WEIGHT; PEPTIDES; PROTEIN ARRAY ANALYSIS; PROTEINS; SERUM ALBUMIN; SYNDROME;

EID: 11844305921     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Egashira K. Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1. Hypertension 2002;(3 Pt 2):834-41.
2. Angiolillo DJ, Biasucci LM, Liuzzo G, Crea F. Inflammation in acute coronary syndromes: mechanisms and clinical implications. Rev Esp Cardiol 2004;57:433-46.
3. Bhatia V, Bhatia R, Dhindsa S, Virk A. Vulnerable plaques, inflammation and newer imaging modalities. J Postgrad Med 2003;49:361-8.
4. Blake GJ. Inflammatory biomarkers of the patient with myocardial insufficiency. Curr Opin Crit Care 2003;9: 369-74.
5. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000;21: 1164-77.
6. Banez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam B et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003;170:442-6.
7. Cazares L, Adam BL, Ward MD, Nasim S, Schellhammer PF, Semmes OF et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002;8:2541.
8. Vlahou A, Schellhammer PF, Mendrinos, S, Patel K, Kondylis FI, Gong L et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158: 1491-502.
9. Kereiakes DJ, Grines C, Fry E, Estente P, Hoppensteadt D, Midei M et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13:272-8.
10. Coombes KR, Fritsche HA, Clarke C, Chen J, Bagerly KA, Morris JS et al. Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 2003;49:1615-23.
11. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
12. Cho WCS, Yip TTC, Yip C, Yip V, Thulasiraman V, Ngan RKC et al. Identification of serum amyloid A protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteimic profiling. Clin Cancer Res 2004;10:43-52.
13. Uno F, Sasaki J, Nishizaki M, Carboni G, Xu K, Atkinson EN et al. Myristoylation of the Fus1 is required for tumor suppression in human lung cancer cells. Cancer Res 2004;64:2969-76.
14. Sun B, Rempel HC, Pulliam L. Loss of macrophage-secreted lysozyme in HIV-1-associated dementia detected by SELDI-TOF mass spectrometry. AIDS 2004;29:1009-12.
15. Fareed J, Hussain W, Florian-Kujawski M, Morgan M, Hoppensteadt D, Leya F. Plasma protein profiling using surface enhanced laser desorption/ionization (SELDI) identification of unique molecular components with 10-12 kDa in inflammatory state: diagnostic and prognostic implications. FASEB J 2004;18 abstract 151.2.
16. Mendrino SE, Lewis MM, and DJ. SELDI-TOF mass spectrometry (SELDI-TOF MS) identifies unique protein profiles in cerebrospinal fluid from inflammatory and neoplastic central nervous system diseases. FASEB J 2004;18-abstract 151.1.